Khoja v. Orexigen Therapeutics, Inc.

District Court, S.D. California·Decided November 30, 2021·No. 3:15-cv-00540·Unknown

Opinion

KARIM KHOJA, et al., on behalf of Case No.: 15-cv-00540-JLS-AGS himself and all others similarly situated, ORDER: Plaintiffs, v. (1) GRANTING UNOPPOSED MOTION FOR FINAL APPROVAL OREXIGEN THERAPEUTICS, INC., et OF SETTLEMENT AND PLAN OF al., ALLOCATION; Defendants. (2) GRANTING MOTION FOR AN AWARD OF ATTORNEYS’ FEES AND EXPENSES; AND (3) ENTERING JUDGMENT

[ECF Nos. 149; 150]

Presently before the Court are Lead Plaintiff Karim Khoja’s Unopposed Motions for: (1) Final Approval of Settlement and Plan of Allocation (“Final Approval Motion”) (ECF No. 149); and (2) an Award of Attorneys’ Fees and Litigation Expenses (“Fees Motion”) (ECF No. 150). The Court held a Final Approval Hearing regarding both motions on October 28, 2021. (ECF No. 154.) As set forth during the Hearing, because the Settlement and Plan of Allocation are fair, reasonable, and adequate, the Court GRANTS the Final Approval Motion. Further, because the requested attorneys’ fees, litigation expenses, and incentive award, are reasonable the Court GRANTS the unopposed Fees Motion. This case began over six years ago on March 10, 2015, when the first of three initial complaints in this action was filed alleging that Defendant Orexigen Therapeutics, Inc. (“Orexigen”) “made materially misleading statements when it disclosed confidential 25[ percent] interim data from a large-scale clinical trial . . . of its weight loss drug, Contrave,” on March 3, 2015. (ECF No. 149-2 (“Abadou Decl.”) ¶ 2.) The news that Contrave may demonstrate cardioprotective benefits caused Orexigen’s stock to close “31[ percent] higher than it did the day prior.” (Id.) A March 5, 2015 Forbes.com article, however, reported that “a senior FDA official condemned [Orexigen]’s disclosure, . . . causing the stock price to plummet and erasing more than $280 million in market capitalization.” (Id.) Several related cases were filed premised on the same facts (id. ¶ 11), and on June 22, 2015, the Honorable M. James Lorenz ordered the cases consolidated, appointed Karim Khoja (“Lead Plaintiff” or “Plaintiff”) as lead plaintiff, and approved Kahn Swick & Foti, LLP (“Lead Counsel”) as lead counsel (ECF No. 43). (Abadou Decl. ¶ 12.) On June 26, 2015, Judge Lorenz recused himself from the case, and this Court was reassigned. (ECF No. 46.) On August 20, 2015, Plaintiff filed a Consolidated Complaint (ECF No. 55), which added allegations of further misleading statements made by Orexigen on March 3 and May 8, 2015. (Abadou Decl. ¶¶ 12–13.) Defendants Orexigen, Joseph P. Hagan, Michael A. Narachi, and Preston Klassen (collectively, “Defendants”) filed a Motion to Dismiss the Consolidated Complaint (ECF No. 62), which the Court granted with leave to amend (ECF No. 76). (Abadou Decl. ¶ 14.) Thereafter, Plaintiff requested that the Court enter judgment in Defendants’ favor so he could pursue an appeal (ECF No. 77) and subsequently appealed the Court’s dismissal decision (ECF No. 80). (Abadou Decl. ¶ 14.) On March 12, 2018, while the appeal was pending, Orexigen filed for Chapter 11 bankruptcy, and an automatic stay halted further proceedings against Orexigen, but not the remaining defendants (collectively, the “Individual Defendants”). (Id. ¶¶ 16, 36; see also id. ¶¶ 46–52.) On August 13, 2018, the Ninth Circuit affirmed in part and reversed in part the Court’s dismissal of the Consolidated Complaint (ECF No. 93). (Abadou Decl. ¶¶ 15, 37.) The Individual Defendants filed petitions for panel rehearing and rehearing en banc (ECF No. 85), but the Ninth Circuit denied the petitions (ECF No. 86). (Abadou Decl. ¶¶ 38– 41.) The Individual Defendants then filed a petition for writ of certiorari with the Supreme Court, but the Court denied certiorari (ECF No. 108). (Abadou Decl. ¶¶ 43–45.) Following an Appeal Mandate Hearing on January 7, 2019, (ECF No. 92), this Court issued a briefing schedule for the Individual Defendants to file a renewed motion to dismiss (ECF No. 97). (Abadou Decl. ¶ 53.) On September 23, 2019, the Court granted in part and denied in part the Individual Defendants’ Renewed Motion to Dismiss (ECF Nos. 98; 110). (Abadou Decl. ¶ 55.) On October 17, 2019, Plaintiff filed a Consolidated Amended Complaint (“CAC”) (ECF No. 111), which the Individual Defendants moved to dismiss (ECF No. 114). (Abadou Decl. ¶¶ 56–57.) On March 13, 2020, the parties participated in a day-long mediation facilitated by Jed Melnick, Esq., of JAMS. (Id. ¶¶ 63–64.) After reaching an impasse, the parties adjourned but agreed that they would resume settlement discussions after the Court ruled on the Individual Defendants’ pending Partial Motion to Dismiss. (Id. ¶ 64.) On May 19, 2020, after Orexigen’s Wind Down Administrator, Province, Inc. (“Province”), filed a status report with the Ninth Circuit reporting that the bankruptcy stay had been lifted, the Ninth Circuit extended its prior order to Orexigen, and the mandate, which noted the substitution of Province for Orexigen, was spread to this Court on July 10, 2020 (ECF No. 134). (See Abadou Decl. ¶ 59.) On November 2, 2020, the Court granted the Individual Defendants’ Partial Motion to Dismiss (ECF No. 139). (Abadou Decl. ¶ 62.) Thereafter, the parties resumed settlement negotiations, and, after several weeks of additional negotiations, agreed to accept a mediator’s proposal of $4.8 million. (Id. ¶¶ 64–65.) On December 9, 2020, the parties completed and executed a Settlement Term Sheet and filed a Notice of Settlement (ECF No. 140) requesting that the Court set a date for Plaintiff to move for preliminary approval of the parties’ settlement. (Abadou Decl. ¶ 66.) The Court subsequently ordered Plaintiff to file a motion for preliminary approval of the settlement by February 12, 2021 (ECF No. 141). (Abadou Decl. ¶ 66.) Plaintiff filed an Unopposed Motion for Preliminary Approval of Proposed Settlement on February 12, 2021, (ECF No. 142), and the Court granted preliminary approval on April 22, 2021 (ECF No. 147). (Abadou Decl. ¶ 68.) On May 18, 2021, the $4.8 million Settlement Amount was paid into an interest-bearing escrow account on behalf of the Settlement Class. (Id. ¶ 69.) Plaintiff’s Final Approval and Fees Motions now follow. The Proposed Settlement1 preliminarily approved by this Court defines the Settlement Class as: “all Persons who purchased or otherwise acquired Orexigen publicly traded securities between March 3, 2015 and May 12, 2015, inclusive,” excluding “Defendants, all directors and officers of Orexigen (whether current or former), each of their respective immediate family members, and entities in which any such excluded person holds a controlling interest.”

Free access — add to your briefcase to read the full text and ask questions with AI

Khoja v. Orexigen Therapeutics, Inc., (S.D. Cal. 2021).

Khoja v. Orexigen Therapeutics, Inc. (Khoja v. Orexigen Therapeutics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
United States v. Walter Kenneth Lee
955 F.2d 14 (Fifth Circuit, 1992)
Boyd v. Bechtel Corp.
485 F. Supp. 610 (N.D. California, 1979)
In Re Immune Response Securities Litigation
497 F. Supp. 2d 1166 (S.D. California, 2007)
In Re Omnivision Technologies, Inc.
559 F. Supp. 2d 1036 (N.D. California, 2008)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
Vizcaino v. Microsoft Corp.
290 F.3d 1043 (Ninth Circuit, 2002)
Nunez v. Bae Sys. San Diego Ship Repair Inc.
292 F. Supp. 3d 1018 (S.D. California, 2017)
Bellinghausen v. Tractor Supply Co.
306 F.R.D. 245 (N.D. California, 2015)
In re Linkedin User Privacy Litigation
309 F.R.D. 573 (N.D. California, 2015)
Williams v. Vukovich
720 F.2d 909 (Sixth Circuit, 1983)